KR102081493B1 - 상처 치유 방법 - Google Patents

상처 치유 방법 Download PDF

Info

Publication number
KR102081493B1
KR102081493B1 KR1020177020505A KR20177020505A KR102081493B1 KR 102081493 B1 KR102081493 B1 KR 102081493B1 KR 1020177020505 A KR1020177020505 A KR 1020177020505A KR 20177020505 A KR20177020505 A KR 20177020505A KR 102081493 B1 KR102081493 B1 KR 102081493B1
Authority
KR
South Korea
Prior art keywords
wound
leu
lactic acid
ala
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177020505A
Other languages
English (en)
Korean (ko)
Other versions
KR20170097194A (ko
Inventor
에블리나 바게스조
Original Assignee
일리야 팔마 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일리야 팔마 에이비 filed Critical 일리야 팔마 에이비
Priority to KR1020207004865A priority Critical patent/KR102297619B1/ko
Publication of KR20170097194A publication Critical patent/KR20170097194A/ko
Application granted granted Critical
Publication of KR102081493B1 publication Critical patent/KR102081493B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177020505A 2014-12-23 2015-12-23 상처 치유 방법 Active KR102081493B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207004865A KR102297619B1 (ko) 2014-12-23 2015-12-23 상처 치유 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1451658 2014-12-23
SE1451658-7 2014-12-23
PCT/EP2015/081146 WO2016102660A1 (en) 2014-12-23 2015-12-23 Methods for wound healing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207004865A Division KR102297619B1 (ko) 2014-12-23 2015-12-23 상처 치유 방법

Publications (2)

Publication Number Publication Date
KR20170097194A KR20170097194A (ko) 2017-08-25
KR102081493B1 true KR102081493B1 (ko) 2020-02-26

Family

ID=55080095

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177020505A Active KR102081493B1 (ko) 2014-12-23 2015-12-23 상처 치유 방법
KR1020207004865A Active KR102297619B1 (ko) 2014-12-23 2015-12-23 상처 치유 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207004865A Active KR102297619B1 (ko) 2014-12-23 2015-12-23 상처 치유 방법

Country Status (9)

Country Link
US (3) US10696974B2 (enExample)
EP (2) EP3237622B1 (enExample)
JP (2) JP6581208B2 (enExample)
KR (2) KR102081493B1 (enExample)
CN (2) CN113403244B (enExample)
AU (2) AU2015370982B2 (enExample)
CA (1) CA2971520C (enExample)
ES (2) ES3048233T3 (enExample)
WO (1) WO2016102660A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3408378B1 (en) 2016-01-25 2022-01-12 NantCell, Inc. Nk cells with altered cxcl12/cxcr4 signaling
BR112019007812A2 (pt) * 2016-10-31 2019-07-16 Kimberly Clark Co métodos para arquivar e de recriar um microbioma.
US20240024388A1 (en) * 2017-02-17 2024-01-25 The University Of British Columbia Probiotic compositions and uses thereof
CN110157733A (zh) * 2018-02-11 2019-08-23 四川大学 重组mIL-22BP载体、脂质体复合物及其制备方法和用途
EP3827102A1 (en) * 2018-07-24 2021-06-02 Biogaia AB Therapeutic methods using bacterial strains which are capable of increasing adenosine levels
US11911424B2 (en) * 2018-07-24 2024-02-27 Biogaia Ab Selection and use of melatonin supporting bacteria to reduce infantile colic
CN109112155A (zh) * 2018-08-02 2019-01-01 南昌大学 乳酸乳球菌mg1363的构建及其在治疗细菌性阴道炎中的应用
CN109517772A (zh) * 2018-10-30 2019-03-26 南昌大学 一种乳酸乳球菌mg1363的构建及其在治疗产妇乳头皲裂中的应用
CN109234298A (zh) * 2018-10-30 2019-01-18 南昌大学 一种卷曲乳杆菌atcc55221的构建及其在治疗产妇乳头皲裂中的应用
JP7045671B2 (ja) * 2018-11-12 2022-04-01 有限会社バイオ研 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材
JP7525911B2 (ja) * 2019-06-24 2024-07-31 メンデス・ソシエタ・ア・レスポンサビリタ・リミタータ プロバイオティクスを含む抗菌および再上皮化作用を有する組成物
CN110623792B (zh) * 2019-09-23 2022-05-06 温州医科大学附属第一医院 一种医学敷料及其制备方法
CN114470007B (zh) * 2020-11-13 2024-10-18 葡萄王生技股份有限公司 含乳酸菌发酵产物之皮肤创伤外用组合物及其用途
JPWO2023063314A1 (enExample) 2021-10-11 2023-04-20
WO2023118327A1 (en) 2021-12-22 2023-06-29 Ilya Pharma Ab Live bacteria as excipients for proteins
KR20240131363A (ko) * 2021-12-29 2024-08-30 일리야 팔마 에이비 요법-유도된 장병증의 치료
KR102752056B1 (ko) * 2023-07-12 2025-01-13 전남대학교 산학협력단 락토바실러스 루터리(Lactobacillus reuteri) NCHBL-005 균주를 포함하는 창상 예방 또는 치료, 피부 재생 촉진용 조성물
GB202405882D0 (en) 2024-04-26 2024-06-12 Ilya Pharma Ab Treatment of mdr infections
CN118948906B (zh) * 2024-10-16 2025-02-14 温州医科大学附属第一医院 一种促进创面愈合的乳酸杆菌生物膜衍生物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014806A2 (en) * 1995-10-20 1997-04-24 Cambridge University Technical Services Limited Delivery of biologically active polypeptides

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2279461A1 (en) * 1997-02-07 1998-08-13 Shionogi & Co., Ltd. Novel mouse cxc chemokine receptor
ES2272311T3 (es) 1999-07-05 2007-05-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Suministro de peptidos trebol.
CA2311201A1 (en) 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US7776564B2 (en) * 2004-04-30 2010-08-17 Five Prime Therapeutics, Inc. Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use
WO2006018446A2 (en) 2004-08-20 2006-02-23 Actogenix Nv Method to improve lactococcus preservation
JP5049973B2 (ja) 2005-08-30 2012-10-17 アクトジェニックス・エヌブイ 慢性全腸炎の治療のための、抗−ＴＮＦα産生乳酸菌
US20080254014A1 (en) 2005-10-03 2008-10-16 Actogenix N V Use of Recombinant Yeast Strain Producing an Anti-Inflammatory Compound to Treat Colitis
DK2119450T3 (da) 2005-11-29 2013-05-06 Actogenix Nv Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener
US8852916B2 (en) 2010-01-22 2014-10-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with microorganisms
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
EP3255149A3 (en) 2006-05-02 2018-04-18 Intrexon Actobiotics NV Microbial intestinal delivery of obesity related peptides
CA2672229A1 (en) 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
WO2008074331A1 (en) 2006-12-19 2008-06-26 Ferrosan A/S Wound or tissue dressing comprising lactic acid bacteria
RU2009127718A (ru) 2006-12-19 2011-01-27 Ферросан А/С (Dk) Раневой или тканевой перевязочный материал, содержащий молочнокислые бактерии
CN101605900B (zh) 2007-01-12 2014-04-23 阿克图杰尼斯公司 乳球菌启动子和其用途
BRPI0807857A2 (pt) 2007-01-25 2014-05-27 Actogenix Nv Tratamento de doença imune por meio de distribuição através da mucosa de antígenos.
US20110044945A1 (en) * 2007-02-08 2011-02-24 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of multiple sclerosis and methods of using same
EP2164512A2 (en) 2007-06-20 2010-03-24 Actogenix N.V. Methods and compositions for treating mucositis
ATE543507T1 (de) 2007-11-07 2012-02-15 Ono Pharmaceutical Co Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung
AU2008338525B2 (en) 2007-12-14 2015-04-02 Juventas Therapeutics, Inc. Compositions and methods of promoting wound healing
US8367109B2 (en) 2008-04-09 2013-02-05 Brookhaven Science Associates, Llc Microbes encapsulated within crosslinkable polymers
JP2012504116A (ja) 2008-09-29 2012-02-16 アクトジェニックス・エヌブイ 粘膜での微生物のコロニー形成の低減
US20100143305A1 (en) * 2008-12-08 2010-06-10 James Allen Lemke Treatment of hiv and aids using probiotic lactobacillus reuteri
CN102421894A (zh) 2009-04-21 2012-04-18 迈阿密大学 用于促进局部缺血性和糖尿病性创面愈合的组合物、试剂盒和方法
EP2243487A1 (en) 2009-04-23 2010-10-27 Actogenix N.V. Enteric coated formulation
ES2425385T3 (es) 2009-04-30 2013-10-15 Actogenix N.V. Crioprotectores para la liofilización de las bacterias de ácido láctico
US20100310514A1 (en) * 2009-06-04 2010-12-09 Chi Hin Cho Anti-Inflammatory Bacteria
CL2009001506A1 (es) 2009-07-01 2009-09-25 Univ Concepcion Parche o aposito a base de hidrocoloides compuesto por una lamina de gelatina reticulada que comprende cepas viables probioticas productoras de acido lactico de lactobacillus acidophilus dsm 17371, un agente reticulante y un agente plastificante; y proceso para elaborar dicho parche.
CA2772610C (en) 2009-08-28 2018-01-23 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
EP3192873A1 (en) 2009-09-29 2017-07-19 Intrexon Actobiotics NV Lactobacillus and streptococcus promoters and uses thereof
GB2482536B (en) * 2010-08-05 2013-07-24 Hera Pharmaceuticals Inc Expression of antibody or a fragment thereof in lactobacillus
CN101985052B (zh) 2010-08-31 2013-11-06 中国人民解放军第二军医大学 自动捕获内皮祖细胞促进血管化的皮肤替代物及其构建方法
WO2012150269A1 (en) 2011-05-03 2012-11-08 Dupont Nutrition Biosciences Aps Probiotic bacteria for the topical treatment of skin disorders
EP2714912B1 (en) 2011-06-01 2018-05-02 Intrexon Actobiotics NV Polycistronic expression system for bacteria
HUE038830T2 (hu) 2011-09-23 2018-11-28 Intrexon Actobiotics Nv Módosított gram-pozitív baktériumok és alkalmazásaik
CN103917639B (zh) 2011-09-23 2017-09-26 英特瑞克斯顿阿克图比奥帝克斯有限公司 经修饰的革兰氏阳性细菌及其用途
GB201206599D0 (en) * 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
AU2014233266A1 (en) 2013-03-15 2015-10-22 Juventas Therapeutics, Inc. The use of SDF-1 to mitigate scar formation
WO2014146202A1 (en) * 2013-03-18 2014-09-25 London Health Sciences Centre Research Inc. Bacteria for the prevention, treatment and diagnosis of breast cancer
EP4091609A1 (en) 2013-04-29 2022-11-23 Medregen, LLC Wound healing via autologous stem cell mobilization
WO2016124239A1 (en) 2015-02-04 2016-08-11 Aurealis Oy Recombinant probiotic bacteria for use in the treatment of a skin dysfunction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014806A2 (en) * 1995-10-20 1997-04-24 Cambridge University Technical Services Limited Delivery of biologically active polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Medical Hypotheses. Vol. 73, No. 5, 페이지 860 (2009.11.)

Also Published As

Publication number Publication date
KR20170097194A (ko) 2017-08-25
JP2018502600A (ja) 2018-02-01
AU2015370982A1 (en) 2017-07-13
CN113403244B (zh) 2022-08-19
JP7033109B2 (ja) 2022-03-09
EP3735979B1 (en) 2025-08-13
CN113403244A (zh) 2021-09-17
EP3735979C0 (en) 2025-08-13
AU2019204290A1 (en) 2019-07-04
US20230093013A1 (en) 2023-03-23
US20180187202A1 (en) 2018-07-05
CA2971520C (en) 2024-04-09
EP3237622B1 (en) 2021-02-24
US10696974B2 (en) 2020-06-30
WO2016102660A1 (en) 2016-06-30
ES2864373T3 (es) 2021-10-13
US11473091B2 (en) 2022-10-18
CN107208107A8 (zh) 2017-12-26
CN107208107A (zh) 2017-09-26
KR102297619B1 (ko) 2021-09-02
AU2015370982B2 (en) 2019-03-21
JP6581208B2 (ja) 2019-09-25
EP3735979A1 (en) 2020-11-11
JP2020005646A (ja) 2020-01-16
AU2019204290B2 (en) 2021-12-16
US20200299703A1 (en) 2020-09-24
KR20200020994A (ko) 2020-02-26
CA2971520A1 (en) 2016-06-30
EP3237622A1 (en) 2017-11-01
CN107208107B (zh) 2021-07-09
ES3048233T3 (en) 2025-12-09

Similar Documents

Publication Publication Date Title
AU2019204290B2 (en) Methods for wound healing
CN107438666B (zh) 重组益生菌
KR20160005333A (ko) 흉터 형성을 완화시키기 위한 sdf-1의 용도
KR101411839B1 (ko) Ａｂｃ 트랜스포터를 통한 ｅｇｆ 분비 재조합 미생물 및 이를 유효성분으로 포함하는 소화기 궤양 개선 또는 치료용 조성물
HK40061829A (en) Methods for wound healing
HK40061829B (en) Methods for wound healing
KR101799300B1 (ko) Ｃｌａｓｐ２를 이용한 상처 치유 또는 피부 재생용 조성물
JP2024538854A (ja) 皮膚状態を治療するための組成物及び方法
Yong et al. Stability analysis of recombinant human TFF2 and its therapeutic effect on burn-induced gastric injury in mice
US20170266354A1 (en) Cell-Based Device For Local Treatment With Therapeutic Protein
WO2026026676A1 (zh) 一种重组胶原蛋白及其应用
Gardlik A non-specific effect of orally administered Escherichia coli
HK1242736A1 (en) Methods for wound healing
HK1242736B (en) Methods for wound healing

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 7